Sirio Pharma Co., Ltd. (300791) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Sirio Pharma Co., Ltd.

Why is Sirio Pharma Co., Ltd. ?

Flat results in Sep 25

INTEREST COVERAGE RATIO(Q) Lowest at 447.45
CASH AND EQV(HY) Lowest at CNY 1,195.3 MM
DEBT-EQUITY RATIO (HY) Highest at 41.48 %

With ROE of 11.90%, it has a very expensive valuation with a 2.88 Price to Book Value

Over the past year, while the stock has generated a return of -9.66%, its profits have fallen by -11.7%
At the current price, the company has a high dividend yield of 1.7

Below par performance in long term as well as near term

Along with generating -9.66% returns in the last 1 year, the stock has also underperformed China Shanghai Composite in the last 3 years, 1 year and 3 months

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Sirio Pharma Co., Ltd. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Sirio Pharma Co., Ltd.

-6.39%

-0.35

47.35%

China Shanghai Composite

13.33%

0.90

14.74%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

18.94%

EBIT Growth (5y)

13.23%

EBIT to Interest (avg)

52.77

Debt to EBITDA (avg)

0.54

Net Debt to Equity (avg)

0.23

Sales to Capital Employed (avg)

1.03

Tax Ratio

8.83%

Dividend Payout Ratio

35.93%

Pledged Shares

Institutional Holding

ROCE (avg)

12.28%

ROE (avg)

10.53%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

2.88

EV to EBIT

22.05

EV to EBITDA

12.46

EV to Capital Employed

2.42

EV to Sales

1.94

PEG Ratio

Dividend Yield

1.72%

ROCE (Latest)

10.97%

ROE (Latest)

11.90%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bearish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Bullish

Dow Theory

Mildly Bearish

OBV

No Trend

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

8What is working for the Company

OPERATING CASH FLOW(Y)

Highest at CNY 699.19 MM

ROCE(HY)

Highest at 13.6%

RAW MATERIAL COST(Y)

Fallen by -7.94% (YoY

NET SALES(Q)

Highest at CNY 1,249.55 MM

PRE-TAX PROFIT(Q)

Highest at CNY 106.4 MM

EPS(Q)

Highest at CNY 0.32

-8What is not working for the Company

INTEREST COVERAGE RATIO(Q)

Lowest at 447.45

CASH AND EQV(HY)

Lowest at CNY 1,195.3 MM

DEBT-EQUITY RATIO (HY)

Highest at 41.48 %

DEBTORS TURNOVER RATIO(HY)

Lowest at 5.58 times

OPERATING PROFIT(Q)

Lowest at CNY 119.56 MM

OPERATING PROFIT MARGIN(Q)

Lowest at 9.57 %

Here's what is working for Sirio Pharma Co., Ltd.

Operating Cash Flow

Highest at CNY 699.19 MM

in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (CNY MM)

Net Sales

Highest at CNY 1,249.55 MM

in the last five periods

MOJO Watch

Near term sales trend is positive

Net Sales (CNY MM)

Pre-Tax Profit

Highest at CNY 106.4 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (CNY MM)

EPS

Highest at CNY 0.32

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (CNY)

Raw Material Cost

Fallen by -7.94% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Sirio Pharma Co., Ltd.

Interest Coverage Ratio

Lowest at 447.45

in the last five periods

MOJO Watch

The company's ability to manage interest payments is deteriorating

Operating Profit to Interest

Operating Profit

Lowest at CNY 119.56 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is negative

Operating Profit (CNY MM)

Operating Profit Margin

Lowest at 9.57 %

in the last five periods

MOJO Watch

Company's profit margin has deteriorated

Operating Profit to Sales

Cash and Eqv

Lowest at CNY 1,195.3 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents

Debt-Equity Ratio

Highest at 41.48 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Debtors Turnover Ratio

Lowest at 5.58 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio